summit clinical trial tirzepatide An Observational Study of Cardiovascular Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists Another "Positive" Heart Failure Trial

These are rare but include Type A insulin resistance syndrome and Donohue syndrome

Semaglutide is a synthetic 31-amino-acid polypeptide analog of the endogenous glucagon-like peptide-1 (GLP-1), belonging to the class of drugs labeled glucagon-like peptide-1 receptor agonists (GLP-1 RAs)

Weight Loss Specials Our Proven Weight Loss Medications We offer one of two weight loss medications

Looking at the absolute figures, this is how the study breaks down: 47 (2.9%) patients on semaglutide experienced a non-fatal heart attack, compared to 64 (3.9%) on placebo

Tirzepatide, a dual glucagon-like peptide-1 (GIP) and GLP-1RAs, administered once weekly at a 15 mg dose, resulted in an average weight loss of 20.9% over 72 weeks (Jastreboff et al., 2022), driven by its synergistic effects on appetite regulation, energy intake reduction, and fat mass decrease (Heise et al., 2023)